Brind.

BioCryst Pharmaceuticals adhered to Nasdaq Listing Rule 5635(c)(4) on September 3, 2025.

4 reports, 1 independent Updated Jul 2
Gone quiet
Reports
4
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

BioCryst Pharmaceuticals adhered to Nasdaq Listing Rule 5635(c)(4) on September 3, 2025.

Who's involved

What this event is mainly about
BioCryst Pharmaceuticals

How it developed

Newest first. Tap a step to see who reported it.
  1. BioCryst Pharmaceuticals achieved adherence to Nasdaq Listing Rule 5635(c)(4).1 source
  2. BioCryst achieved compliance with Nasdaq Listing Rule 5635(c)(4) on July 3, 2025.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced
  • GlobeNewswireBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced t
  • Unknown outlet
1 more outlet ran the same wire story